Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Genprex, Inc. (GNPX)

Genprex to present TUSC2 aging research at GSA 2026 meeting in November

Neutral Impact 2 of 5 product/contract Written later

Genprex said research from its sponsored collaboration with Meharry Medical College will be featured at the Gerontological Society of America 2026 Annual Scientific Meeting, November 4-7, 2026. The work examines the TUSC2 gene, used in its lead oncology candidate REQORSA, in mitochondrial biology and aging-related processes. The company said further research is needed to determine whether the findings could support future therapeutic development.

Key points

  • Poster titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for Wednesday, Nov. 4, 2026, 6:00-7:15 p.m. ET
  • Presenter is Mark S. Berger, MD, Chief Medical Officer of Genprex
  • Collaboration with Meharry Medical College was established in 2024
  • The filing does not state any financial terms or effects on the company's results

The filing

CompanyGenprex, Inc. (GNPX)
Form8-K, current report
Filed with the SECOct 28, 2026, 7:01 AM ET
Accession number0001437749-26-033700

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.